# Effects of Dalfampridine on Cognition in Multiple Sclerosis

> **NCT02006160** · PHASE2,PHASE3 · COMPLETED · sponsor: **State University of New York at Buffalo** · enrollment: 61 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** dalfampridine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02006160
- **Lead sponsor:** State University of New York at Buffalo
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2020-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02006160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02006160, "Effects of Dalfampridine on Cognition in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02006160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*